期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
护肝药物对心脏体外循环术后肝功能异常患者的疗效分析
1
作者 张春娟 毛琦琦 赵蕊 《中国药物与临床》 2025年第4期261-266,共6页
目的分析护肝药物干预对体外循环(CPB)术后指标异常患者的疗效。方法回顾性收集2022—2023年浙江大学医学院附属邵逸夫医院CPB术后入重症监护病房(ICU)出现肝功能指标异常(aLFT)的危重症患者数据,按照有无使用护肝药物将其分为对照组和... 目的分析护肝药物干预对体外循环(CPB)术后指标异常患者的疗效。方法回顾性收集2022—2023年浙江大学医学院附属邵逸夫医院CPB术后入重症监护病房(ICU)出现肝功能指标异常(aLFT)的危重症患者数据,按照有无使用护肝药物将其分为对照组和观察组,观察组接受护肝药物的对症治疗,对照组不接受护肝治疗。观察主要结局是肝功能好转时间,次要结局是总住院时间、CPB术后住院时间。结果共纳入88例患者,主要表现有转氨酶升高和胆红素升高,出现aLFT峰值的中位时间是1 d。38例患者接受护肝治疗,2组aLFT好转时间对比,差异无统计学意义,总住院时间和术后住院时间对比,差异无统计学意义;Lasso回归和Cox回归分析发现术后是否伴肾损害是aLFT好转时间的独立危险因素(P<0.05)。结论CPB术前肝功能正常,术后早期(3 d内)出现的aLFT可能是短暂/一过性的,护肝治疗药物的干预差异无统计学意义,对其有效性不高。 展开更多
关键词 体外循环手术 肝疾病 护肝治疗 治疗结果 预后
暂未订购
Hepatoprotective properties of oleanolic and ursolic acids in anti-tubercular drug-induced liver damage 被引量:10
2
作者 Gabriel A.Gutiérrez-Rebolledo Georgina A.Siordia-Reyes +1 位作者 Mariana Meckes-Fischer Adelina Jiménez-Arellanes 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2016年第7期625-632,共8页
Objective:To estimate to what extent the mixture of ursolic acid and oleanolic acid,in addition to the antitubercular standard regime,affects the hepatotoxicity profile.Methods:Liver injury was induced in male BALB/c ... Objective:To estimate to what extent the mixture of ursolic acid and oleanolic acid,in addition to the antitubercular standard regime,affects the hepatotoxicity profile.Methods:Liver injury was induced in male BALB/c mice by administering,per os and daily for 11 weeks,a combination of anti-Tubercular(anti-TB) agents Rifampicin(10 mg/kg),Isoniazid(10 mg/kg),and Pyrazinamide(30 mg/kg).The ursolic acid and oleanolic acid mixture at doses of 100 or 200 μg/mouse/day was subcutaneously injected throughout the entire study period(11 weeks).Biochemical and hematological analysis was supplemented by liver histological examination.Results:Animals treated with the mixture of triterpenic acids exhibited significantly decreased aspartate transaminase and alanine aminotransferase levels and amelioration of the histopathological alterations produced by the anti-TB drugs.Conclusions:The triterpene mixture is able to prevent the steatosis induced by the anti-TB drugs. 展开更多
关键词 Ursolic ACID Oleanolic ACID hepatoprotector effect ANTITUBERCULAR DRUGS TRITERPENES
暂未订购
Hepatoprotective effect of silymarin 被引量:16
3
作者 Nancy Vargas-Mendoza Eduardo Madrigal-Santillán +5 位作者 ngel Morales-González Jaime Esquivel-Soto Cesar Esquivel-Chirino Manuel García-Luna y González-Rubio Juan A Gayosso-de-Lucio José A Morales-González 《World Journal of Hepatology》 CAS 2014年第3期144-149,共6页
The use of medicinal plants in treating illnesses has been reported since ancestral times.In the case of hepatic diseases,several species such as Silybum marianum,Phyllanthus niruri,and Panus giganteus(Berk.)have been... The use of medicinal plants in treating illnesses has been reported since ancestral times.In the case of hepatic diseases,several species such as Silybum marianum,Phyllanthus niruri,and Panus giganteus(Berk.)have been shown to ameliorate hepatic lesions.Silymarin is a natural compound derived from the species Silybum marianum,which is commonly known as Milk thistle.This plant contains at least seven flavoligands and the flavonoid taxifolin.The hepatoprotective and antioxidant activity of silymarin is caused by its ability to inhibit the free radicals that are produced from the metabolism of toxic substances such as ethanol,acetaminophen,and carbon tetrachloride.The generation of free radicals is known to damage cellular membranes and cause lipoperoxidation.Silymarin enhances hepatic glutathione and may contribute to the antioxidant defense of the liver.It has also been shown that silymarin increases protein synthesis in hepatocytes by stimulating RNA polymerase I activity.A previous study on humans reported that silymarin treatment caused a slight increase in the survival of patients with cirrhotic alcoholism compared with untreated controls. 展开更多
关键词 Silybum marianum hepatoprotector LIPOPEROXIDATION SILYMARIN
暂未订购
Standardized bioactive fraction of Phaleria macrocarpa(Proliverenol) prevents ethanol-induced hepatotoxicity via down-regulation of NF-kB-TNFα-caspase-8 pathway 被引量:2
4
作者 Guntur Berlian Olivia Mayasari Tandrasasmita Raymond Rubianto Tjandrawinata 《Asian Pacific Journal of Tropical Biomedicine》 SCIE CAS 2016年第8期686-691,共6页
Objective: To verify that Proliverenol has a potential ability in protecting cells from ethanol-induced hepatotoxicity.Methods: Activity of Proliverenol against ethanol-induced apoptosis was evaluated at m RNA and pro... Objective: To verify that Proliverenol has a potential ability in protecting cells from ethanol-induced hepatotoxicity.Methods: Activity of Proliverenol against ethanol-induced apoptosis was evaluated at m RNA and protein levels in Hep G2 cell exposed to Proliverenol for 1 and 3 h.Results: Proliverenol conferred hepatoprotective activity through increasing cell survival up to 53%–69% via up-regulation of APEX1 DNA repair enzyme for 3.0–4.7 fold and down-regulating of nuclear factor-kB, tumor necrosis factora and caspase-8 expression,allowing them to prevent 4.5–6.9 fold of alanine aminotransferase(ALT) leakage in Hep G2 cells. Our finding revealed that Proliverenol repressed expression of ALT, which is significantly important as possible alternative mechanism for increased blood transaminase activities. In addition, the result also showed that caspase-8 pathway seemed to be involved in the molecular pathway rather than directly inducing mitochondrial damage.Conclusions: The data support our hypothesis that Proliverenol has a potential ability in protecting cells from ethanol-induced hepatotoxicity. We propose that Proliverenol provides hepatoprotective activity through up-regulating expression of APEX1 that repress DNA fragmentation, and down-regulating expression of nuclear factor-kB, tumor necrosis factora and caspase-8, which therefore repress ALT leakage and its expression. 展开更多
关键词 Phaleria macrocarpa hepatoprotector Liver injury CIRRHOSIS HepG2
暂未订购
某院结核门诊6112张保肝药处方专项点评 被引量:2
5
作者 程凯 李娜 +2 位作者 徐建 郭振勇 穆晓攀 《中国药业》 CAS 2023年第8期109-112,共4页
目的为结核患者规范使用保肝药提供参考。方法抽取首都医科大学附属北京胸科医院结核门诊2020年4月至2021年12月使用保肝药的处方6112张,根据《处方管理办法》《医院处方点评管理规范(试行)》《北京市医疗机构处方专项点评指南(试行)》... 目的为结核患者规范使用保肝药提供参考。方法抽取首都医科大学附属北京胸科医院结核门诊2020年4月至2021年12月使用保肝药的处方6112张,根据《处方管理办法》《医院处方点评管理规范(试行)》《北京市医疗机构处方专项点评指南(试行)》中要求,结合处方信息、患者门诊病历及各项检验结果,查阅相关药品说明书、临床指南及专家共识等循证证据,对抽取保肝药处方的适应证、用法与用量、联合用药、用药禁忌证等进行适宜性、规范性专项点评。结果处方不合理率为4.50%(275/6112)。不合理类型主要为无高危因素预防性用药(104张,37.82%),无适应证用药(57张,20.73%),用法与用量不适宜(41张,14.91%),联用3类保肝药(34张,12.36%)等。结论该院仍存在结核患者不合理使用保肝药现象。临床药师应加强对医师的用药宣教,重视保肝药的规范使用,同时持续改进其专项处方点评制度,促进临床合理、规范使用保肝药。 展开更多
关键词 结核 门诊 保肝药 处方点评 合理用药
暂未订购
抗结核治疗中预防应用保肝药临床试验的中文文献系统评价 被引量:12
6
作者 黄爱君 夏情情 +2 位作者 詹思延 张耀文 舒正 《中华流行病学杂志》 CAS CSCD 北大核心 2010年第7期826-827,共2页
我国结核病负担较高,每年仅新发现的初复治病例即达98万,加上原患未治愈者,每年接受治疗的病例超过100万。抗结核治疗使用的一、二线药物均可引起不良反应,其中影响最大且发病率较高的为肝损害。为避免肝损害的发生,目前我国临床... 我国结核病负担较高,每年仅新发现的初复治病例即达98万,加上原患未治愈者,每年接受治疗的病例超过100万。抗结核治疗使用的一、二线药物均可引起不良反应,其中影响最大且发病率较高的为肝损害。为避免肝损害的发生,目前我国临床上常在抗结核治疗开始时,即予保护肝脏的药物。这种预防性使用在其他国家极为少见, 展开更多
关键词 抗结核药 肝损伤 临床试验 保肝药
原文传递
保肝药物防治非酒精性脂肪性肝病临床价值 被引量:11
7
作者 李瑜元 《中国实用内科杂志》 CAS CSCD 北大核心 2009年第5期395-398,共4页
保肝药物包括抗氧化制(维生素E、水飞蓟素、还原型谷胱甘肽、甜菜碱等)和其他类型药物(多烯磷脂酰胆碱、熊去氧胆酸、硫普罗宁、甘草酸制剂、己酮可可碱等),是非酒精性脂肪性肝病(NAFLD)防治的合理选择,但尚无特效药。循证医学显示,其... 保肝药物包括抗氧化制(维生素E、水飞蓟素、还原型谷胱甘肽、甜菜碱等)和其他类型药物(多烯磷脂酰胆碱、熊去氧胆酸、硫普罗宁、甘草酸制剂、己酮可可碱等),是非酒精性脂肪性肝病(NAFLD)防治的合理选择,但尚无特效药。循证医学显示,其可改善临床症状,降低转氨酶,但没有足够证据证实可改善肝脏组织学和延缓疾病进程。保肝药物适用于非酒精性脂肪性肝炎(NASH)患者,一般选用1~2种,应和基础治疗配合,以提高疗效。 展开更多
关键词 保肝药物 非酒精性脂肪性肝病
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部